Skip to content

Study · In vitro (cells) · 2018

7 results

Kisspeptin-10 (KP-10) stimulates osteoblast differentiation through GPR54-mediated regulation of BMP2 expression and activation.

Son HE, Kim KM, Kim EJ, Jang WG

Scientific reports1 Feb 2018Cited by 24 (Europe PMC)

PMID29391507 (opens in a new tab)PMCIDPMC5794871 (opens in a new tab)DOI10.1038/s41598-018-20571-2 (opens in a new tab)PepBankPUB-29391507
Download PDFPubMedAsk about this study
Jump to 7 results

Summary

Kisspeptin-10 (KP-10) acts as a tumor metastasis suppressor via its receptor, G-protein-coupled receptor 54 (GPR54). The KP-10-GPR54 system plays an important role in embryonic kidney development. However, its function in osteoblast differentiation is unknown. Osteoblast differentiation is controlled by a range of hormones and cytokines, such as bone morphogenetic protein (BMPs), and multiple transcription factors, such as Runt-related transcription factor 2 (Runx2), alkaline phosphatase (ALP), and Distal-less homeobox 5 (Dlx5). In the present study, KP-10-treatment significantly increased the expression of osteogenic genes, including mRNA and protein levels of BMP2, in C3H10T1/2 cells. Moreover, KP-10 induced BMP2-luc activity and increased phosphorylation of Smad1/5/9. In addition, NFATc4 specifically mediated KP-10-induced BMP2 gene expression. However, KP-10 treatment did not induce expression of the BMP2 and Runx2 genes in GPR54-/- cells. To examine whether KP-10 induced secretion of BMP2 to the culture medium, we used the conditioned-medium (C.M) of KP-10 treated medium on C3H10T1/2 cells. Dlx5 and Runx2 expressions were higher in GPR54-/- cells treated with C.M than in those treated with KP-10. These results demonstrate that BMP2 protein has an autocrine effect upon KP-10 treatment. Taken together, these findings suggest that KP-10/GPR54 signaling induces osteoblast differentiation via NFATc4-mediated BMP2 expression.
CC BYText from Europe PMC. Highlighted sentences are the source of results.

Results from this study7

7 results from studies that gave the peptide. No result from this study comes from people.

  1. 01LabIn vitro (cells)Efficacy outcome

    In C3H10T1/2 cells, KP-10 treatment significantly increased the expression of osteogenic genes.

    In plain wordsIn cells, KP-10 raised the activity of genes that drive bone-forming cell development.

    Peptide
    Kisspeptin-10
    Outcome
    IncreaseOsteogenic gene expression
    Study

    n: not reported in source

    C3H10T1/2 cells
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    Dose not stated

    Source sentences

    Summary
    In the present study, KP-10-treatment significantly increased the expression of osteogenic genes, including mRNA and protein levels of BMP2, in C3H10T1/2 cells
  2. 02LabIn vitro (cells)Mechanism

    In C3H10T1/2 cells, KP-10 treatment significantly increased BMP2 mRNA and protein levels.

    In plain wordsIn cells, KP-10 raised the amount of BMP2, a bone growth signal.

    Peptide
    Kisspeptin-10
    Outcome
    IncreaseBMP2 mRNA and protein expression
    Study

    n: not reported in source

    C3H10T1/2 cells
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    Dose not stated

    Source sentences

    Summary
    In the present study, KP-10-treatment significantly increased the expression of osteogenic genes, including mRNA and protein levels of BMP2, in C3H10T1/2 cells.
  3. 03LabIn vitro (cells)Mechanism

    In C3H10T1/2 cells, KP-10 increased BMP2-luc reporter activity.

    In plain wordsIn cells, KP-10 switched on the BMP2 gene signal more.

    Peptide
    Kisspeptin-10
    Outcome
    IncreaseBMP2 promoter (BMP2-luc) activity
    Study

    n: not reported in source

    C3H10T1/2 cells
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Moreover, KP-10 induced BMP2-luc activity
  4. 04LabIn vitro (cells)Mechanism

    In C3H10T1/2 cells, KP-10 increased phosphorylation of Smad1/5/9.

    In plain wordsIn cells, KP-10 raised activation of the Smad pathway that carries the BMP signal.

    Peptide
    Kisspeptin-10
    Outcome
    IncreaseSmad1/5/9 phosphorylation
    Study

    n: not reported in source

    C3H10T1/2 cells
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    Dose not stated

    Source sentences

    Summary
    increased phosphorylation of Smad1/5/9.
  5. 05LabIn vitro (cells)Mechanism

    In C3H10T1/2 cells, NFATc4 specifically mediated the KP-10-induced BMP2 gene expression.

    In plain wordsIn cells, a protein called NFATc4 carried the KP-10 signal that switches on BMP2.

    Peptide
    Kisspeptin-10
    Outcome
    Not applicableNFATc4 role in KP-10-induced BMP2 expression
    Study

    n: not reported in source

    C3H10T1/2 cells
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    Dose not stated

    Source sentences

    Summary
    In addition, NFATc4 specifically mediated KP-10-induced BMP2 gene expression.
  6. 06LabIn vitro (cells)Mechanism

    In GPR54-/- cells, KP-10 treatment did not induce expression of the BMP2 and Runx2 genes.

    In plain wordsIn cells that lack the GPR54 receptor, KP-10 did not switch on the BMP2 and Runx2 genes.

    Peptide
    Kisspeptin-10
    Outcome
    No significant changeBMP2 and Runx2 expression in GPR54-/- cells
    Study

    n: not reported in source

    GPR54-/- cells
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    Dose not stated

    Source sentences

    Summary
    However, KP-10 treatment did not induce expression of the BMP2 and Runx2 genes in GPR54-/- cells.
  7. 07LabIn vitro (cells)Mechanism

    In GPR54-/- cells, Dlx5 and Runx2 expression was higher with conditioned medium from KP-10-treated cells than with KP-10 added directly.

    In plain wordsIn cells lacking GPR54, medium from KP-10-treated cells raised Dlx5 and Runx2 more than KP-10 itself.

    Peptide
    Kisspeptin-10
    Outcome
    IncreaseDlx5 and Runx2 expression with conditioned medium
    Study

    n: not reported in source

    GPR54-/- cells
    Comparator
    KP-10 added directly
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Dlx5 and Runx2 expressions were higher in GPR54-/- cells treated with C.M than in those treated with KP-10.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    9 Oct 2026, 18:17 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:04 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.